查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1703335

肌肉痙攣市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、給藥途徑、配銷通路、地區和競爭細分，2020 年至 2030 年

Muscle Spasticity Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球肌肉痙攣市場價值為 41.1 億美元，預計到 2030 年將達到 55.3 億美元，複合年成長率為 5.03%。全球肌肉痙攣市場是更廣泛的醫療保健產業中一個充滿活力且不斷發展的領域，專注於解決肌肉痙攣這一複雜的醫療狀況。肌肉痙攣的特徵是肌肉不自主收縮和僵硬，通常由多發性硬化症、腦性麻痺或脊髓損傷等神經系統疾病引起。多年來，隨著神經系統疾病發病率的不斷上升、醫療技術的進步以及人口老化日益加劇，該市場經歷了顯著的成長和創新。

市場概覽
預測期 2026-2030
2024年市場規模 41.1億美元
2030年市場規模 55.3億美元
2025-2030 年複合年成長率 5.03%
成長最快的領域 網路藥局
最大的市場 北美洲

關鍵市場促進因素

神經系統疾病發生率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

提高認知和教育

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球肌肉痙攣市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類型（巴氯芬、肉毒桿菌、地西泮、丹曲林鈉等）
    • 依給藥途徑（口服、肌肉注射、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 依藥物類型
    • 依給藥途徑
    • 按配銷通路
    • 按地區

第5章：亞太地區肌肉痙攣市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第6章：歐洲肌肉痙攣市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第7章：北美肌肉痙攣市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：南美肌肉痙攣市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第9章：中東和非洲肌肉痙攣市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 12 章：全球肌肉痙攣市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Ipsen Pharma
  • Allergan
  • Acorda Therapeutics, Inc.
  • Merz Pharma
  • Novartis AG
  • Beximco Pharmaceuticals Ltd.
  • Zydus Cadila
  • Porex Corporation
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16878

Global Muscle Spasticity Market was valued at USD 4.11 Billion in 2024 and is expected to reach USD 5.53 Billion in the forecast period with a CAGR of 5.03% through 2030. The global muscle spasticity market is a dynamic and evolving sector within the broader healthcare industry, focused on addressing the complex medical condition of muscle spasticity. Muscle spasticity is characterized by involuntary muscle contractions and stiffness, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, or spinal cord injuries. This market has witnessed significant growth and innovation over the years, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and a growing aging population.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.11 Billion
Market Size 2030USD 5.53 Billion
CAGR 2025-20305.03%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Neurological Disorders

The rising incidence of neurological disorders is a pivotal driver behind the burgeoning growth of the global muscle spasticity market. Neurological conditions such as multiple sclerosis (MS), cerebral palsy, spinal cord injuries, stroke, and Parkinson's disease frequently manifest with muscle spasticity, characterized by involuntary muscle contractions and stiffness that significantly impair patients' quality of life.

Multiple sclerosis, in particular, has seen a notable increase in prevalence. According to the World Health Organization (WHO), over 1.8 million people worldwide are affected by MS, with a higher incidence among young adults and females. This autoimmune disease affects the central nervous system and is a leading contributor to muscle spasticity. As the number of MS cases continues to rise, so does the demand for effective treatments to alleviate the debilitating symptoms associated with the condition. Pharmaceutical companies have responded by developing a range of medications aimed at providing relief and improving the daily lives of patients.

Key Market Challenges

High Treatment Costs

High treatment costs pose a significant hurdle in the global muscle spasticity market, impeding the accessibility of care for individuals grappling with this debilitating condition. Muscle spasticity, characterized by involuntary muscle contractions and stiffness, often results from neurological disorders like multiple sclerosis, cerebral palsy, and spinal cord injuries. While treatment options have advanced, the soaring expenses associated with these therapies present a considerable challenge for both patients and healthcare systems. One of the primary issues driving the high treatment costs is the development and production of specialized medications and medical devices tailored for muscle spasticity management. Pharmaceutical companies invest heavily in research and development to create effective drugs that target the condition's symptoms and underlying causes. These innovative treatments, while offering hope for improved patient outcomes, often come with a substantial price tag, making them financially burdensome for many patients.

Key Market Trends

Increasing Awareness and Education

Increasing awareness and education have become instrumental in propelling the global muscle spasticity market forward. In recent years, concerted efforts by advocacy groups, healthcare organizations, and pharmaceutical companies have led to a significant uptick in public understanding and recognition of this debilitating condition. Muscle spasticity, a common symptom in neurological disorders like multiple sclerosis, spinal cord injuries, and stroke, was often overlooked or misunderstood in the past. However, with increased awareness campaigns and educational initiatives, both patients and healthcare providers are now more informed about its prevalence, symptoms, and available treatment options.

Key Market Players

  • Ipsen Pharma
  • Allergan
  • Acorda Therapeutics, Inc.
  • Merz Pharma
  • Novartis AG
  • Beximco Pharmaceuticals Ltd.
  • Zydus Cadila
  • Porex Corporation
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Muscle Spasticity Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Muscle Spasticity Market, By Drug Type:

  • Baclofen
  • Botulinum Toxin
  • Diazepam
  • Dantrolene Sodium
  • Others

Muscle Spasticity Market, By Route of Administration:

  • Oral
  • Intramuscular
  • Others

Muscle Spasticity Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Muscle Spasticity Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Muscle Spasticity Market.

Available Customizations:

Global Muscle Spasticity Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Muscle Spasticity Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Dantrolene Sodium, Others)
    • 4.2.2. By Route of Administration (Oral, Intramuscular, Others)
    • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Drug Type
    • 4.3.2. By Route of Administration
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Muscle Spasticity Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type
    • 5.2.2. By Route of Administration
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Muscle Spasticity Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Drug Type
        • 5.3.1.2.2. By Route of Administration
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Muscle Spasticity Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Drug Type
        • 5.3.2.2.2. By Route of Administration
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Muscle Spasticity Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Drug Type
        • 5.3.3.2.2. By Route of Administration
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Muscle Spasticity Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Drug Type
        • 5.3.4.2.2. By Route of Administration
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Muscle Spasticity Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Drug Type
        • 5.3.5.2.2. By Route of Administration
        • 5.3.5.2.3. By Distribution Channel

6. Europe Muscle Spasticity Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Muscle Spasticity Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Muscle Spasticity Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Muscle Spasticity Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Muscle Spasticity Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Muscle Spasticity Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. North America Muscle Spasticity Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Muscle Spasticity Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Muscle Spasticity Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Muscle Spasticity Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. South America Muscle Spasticity Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Muscle Spasticity Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Muscle Spasticity Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Muscle Spasticity Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Muscle Spasticity Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Muscle Spasticity Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Muscle Spasticity Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Muscle Spasticity Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Muscle Spasticity Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Ipsen Pharma
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Allergan
  • 14.3. Acorda Therapeutics, Inc.
  • 14.4. Merz Pharma
  • 14.5. Novartis AG
  • 14.6. Beximco Pharmaceuticals Ltd.
  • 14.7. Zydus Cadila
  • 14.8. Porex Corporation
  • 14.9. Teva Pharmaceutical Industries Ltd
  • 14.10. Sun Pharmaceutical Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer